ImmunityBio, Inc. (IBRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$8.48

From 52W high−26.58%

Volume18.06M

Market cap$8.99B

P/E (TTM)—

P/S (TTM)54.2x

Div yield—

Key dataSep 18, 2026

Open

$8.48

From 52W high

−26.58%

Volume

18.06M

Market cap

$8.99B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.6x

P/E (TTM)

—

RSI (14)

54.3

MomentumView details →

1D Return

+0.24%

YTD Return

+317.93%

SummaryUpdated Jun 1, 2026

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing innovative therapies and vaccines to treat cancers and infectious diseases. ImmunityBio operates at the cutting edge of immunotherapy and cell therapy, leveraging the body's immune system to fight diseases that have traditionally been difficult to treat.

Ask drillr about ImmunityBio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−10.6x

EV/Sales

57.0x

P/S (TTM)

54.2x

P/B (TTM)

−8.6x

ProfitabilityView details →

Gross Margin

94.63%

Net Margin

−598.56%

EBITDA Margin

−535.82%

ROE (TTM)

94.81%

ROA (TTM)

−157.89%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+192.92%

EPS YoY

—

FCF YoY

−2.51%

Revenue CAGR 3Y

+678.62%

EPS CAGR 3Y

+35.59%

EBITDA YoY

—

MomentumView details →

1D Return

+0.24%

YTD Return

+317.93%

1Y Return

+203.11%

RSI (14)

54.3

vs 50D SMA

+6.87%

vs 200D SMA

+20.50%

Capital & dividendView details →

Debt/Equity

−0.78x

Current Ratio

5.72x

Quick Ratio

5.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.22

EPS Surprise

−175.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

−42.55%

Rev Surprise

3.10%

Financials snapshotView financials →

Revenue (TTM)

165.79M

Net Income (TTM)

−992.36M

Op. CF (TTM)

−356.50M

Next earningsNov 3, 2026 →

Latest newsMore news →

ImmunityBio (IBRX) shares rose 7.0% in the previous trading session on higher-than-average trading volume.2d ago

Bell & Brown Wealth Advisors LLC acquired a new stake in ImmunityBio, Inc. by purchasing 75,050 shares worth approximately $657,000 in the second quarter.31d ago

Similar companies

中源协和600645.SH Crinetics Pharmaceuticals, Inc.CRNX Suzhou Ribo Life Science Co06938.HK GenFleet Therapeutics (Shanghai) Inc.02595.HK Abivax S.A.ABVX 热景生物688068.SH Find similar companies →

Latest newsMore news →

ImmunityBio (IBRX) shares rose 7.0% in the previous trading session on higher-than-average trading volume.2d ago Bell & Brown Wealth Advisors LLC acquired a new stake in ImmunityBio, Inc. by purchasing 75,050 shares worth approximately $657,000 in the second quarter.31d ago